Equities analysts predict that NuVasive, Inc. (NASDAQ:NUVA) will post sales of $295.19 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for NuVasive’s earnings, with the highest sales estimate coming in at $296.50 million and the lowest estimate coming in at $293.20 million. NuVasive reported sales of $271.65 million during the same quarter last year, which indicates a positive year-over-year growth rate of 8.7%. The company is expected to report its next earnings results on Monday, February 25th.

According to Zacks, analysts expect that NuVasive will report full-year sales of $1.11 billion for the current year. For the next fiscal year, analysts forecast that the company will post sales of $1.17 billion, with estimates ranging from $1.16 billion to $1.19 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow NuVasive.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Tuesday, October 30th. The medical device company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.06). NuVasive had a net margin of 2.24% and a return on equity of 13.87%. The company had revenue of $271.30 million for the quarter, compared to the consensus estimate of $265.70 million. During the same period in the previous year, the business earned $0.52 EPS. NuVasive’s revenue for the quarter was up 9.7% compared to the same quarter last year.

A number of equities research analysts recently weighed in on the company. BidaskClub raised NuVasive from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Zacks Investment Research reaffirmed a “strong sell” rating on shares of NuVasive in a research report on Wednesday, November 14th. ValuEngine cut NuVasive from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. BMO Capital Markets decreased their price target on NuVasive from $70.00 to $68.00 and set a “market perform” rating for the company in a research note on Wednesday, October 31st. Finally, Morgan Stanley decreased their price target on NuVasive from $77.00 to $73.00 and set a “hold” rating for the company in a research note on Wednesday, October 31st. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $67.47.

Shares of NUVA stock opened at $61.50 on Friday. NuVasive has a 1-year low of $44.62 and a 1-year high of $72.41. The stock has a market cap of $3.15 billion, a P/E ratio of 32.20, a P/E/G ratio of 1.84 and a beta of 0.78. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.83 and a current ratio of 3.45.

In other news, insider Matthew Link sold 1,200 shares of the firm’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $62.01, for a total value of $74,412.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.95% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Eagle Asset Management Inc. raised its position in NuVasive by 10.1% during the third quarter. Eagle Asset Management Inc. now owns 1,395,940 shares of the medical device company’s stock valued at $99,083,000 after acquiring an additional 127,979 shares in the last quarter. Dimensional Fund Advisors LP raised its position in NuVasive by 10.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,303,103 shares of the medical device company’s stock valued at $67,919,000 after acquiring an additional 121,467 shares in the last quarter. Victory Capital Management Inc. raised its position in NuVasive by 100.0% during the third quarter. Victory Capital Management Inc. now owns 1,000,605 shares of the medical device company’s stock valued at $71,023,000 after acquiring an additional 500,395 shares in the last quarter. Anchor Capital Advisors LLC raised its position in NuVasive by 1.2% during the third quarter. Anchor Capital Advisors LLC now owns 996,179 shares of the medical device company’s stock valued at $70,709,000 after acquiring an additional 12,202 shares in the last quarter. Finally, Hood River Capital Management LLC raised its position in NuVasive by 261.3% during the second quarter. Hood River Capital Management LLC now owns 866,653 shares of the medical device company’s stock valued at $45,170,000 after acquiring an additional 626,770 shares in the last quarter.

NuVasive Company Profile

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Recommended Story: Cash Flow Analysis in Stock Selection

Get a free copy of the Zacks research report on NuVasive (NUVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.